Pertwee
Roger Pertwee, Aberdeen GB
Patent application number | Description | Published |
---|---|---|
20100286098 | USE OF TETRAHYDROCANNABINOL AND/OR CANNABIDIOL FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease. | 11-11-2010 |
20100292345 | THERAPEUTIC USES OF CANNABIGEROL - The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis. | 11-18-2010 |
20100317729 | NEW PHARMACEUTICAL FORMULATION COMPRISING CANNABIDIOL AND TETRAHYDROCANNABIDIVARIN - The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB | 12-16-2010 |
Roger Pertwee, Wiltshire GB
Patent application number | Description | Published |
---|---|---|
20090306221 | Use for Cannabinoid - The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in 0 the treatment of diseases and conditions benefiting from inverse agonism of the CB | 12-10-2009 |
Roger Guy Pertwee, Aberdeenshire GB
Patent application number | Description | Published |
---|---|---|
20100022611 | 1,5-Diaryl-Pyrazoles As Cannabinoid Receptor Neutral Antagonists Useful As Therapeutic Agents - The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain | 01-28-2010 |